HDAX Therapeutics Announces First Closing of Oversubscribed US $3.2 (CA $4.3) Million Seed Financing
HDAX Therapeutics Announces First Closing of Oversubscribed US $3.2 (CA $4.3) Million Seed Financing TORONTO--HDAX Therapeutics (“HDAX”), a biotechnology company pioneering a novel approach to targeting HDAC6 for the discovery and…
